Figure 7
Effect of BIBB-515 and TAK-475 on chemoimmuno-sensitivity in the PBMCs from CLL patients. The PBMCs were treated with or without 10 μM fludarabine (F), 10 μg/ml rituximab (R) or their combinations (F + R) in the presence or absence of 10 μM either BIBB-515 (B, panel A) or TAK-475 (T, panel B) for 3 days, and cell viability was determined by Trypan blue live-dead cell staining. The values of treated with BIBB-515 (n = 10) or TAK-475 (n = 6) samples were statistically different from the controls (C). *P < 0.05. **P < 0.01.